AN2治療公司與GSK達成合作，共同推進基於硼的結核病治療方法的發展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis

動脈網

2025/11/11

AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病（TB）的新療法。The Gates Foundation will provide an ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582936115"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582936115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582936115?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-11 14:19","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582936115","market":"us","top_or_hot":-1,"title":"AN2治療公司與GSK達成合作，共同推進基於硼的結核病治療方法的發展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","media":"動脈網","content":"<div>\n<p>AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病（TB）的新療法。The Gates Foundation will provide an ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2治療公司與GSK達成合作，共同推進基於硼的結核病治療方法的發展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2治療公司與GSK達成合作，共同推進基於硼的結核病治療方法的發展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-11-11 14:19</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病（TB）的新療法。The Gates Foundation will provide an ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛歐洲核心股票組合Acc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","article_id":"2582936115","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582936115","pubTimestamp":1762841940,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis .AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病的新療法。經驗證的LeuRS靶點是多種化合物的基礎，包括用於治療NTM肺病的在研藥物epetraborole、用於治療結核病的在研藥物ganfeborole，以及獲得FDA批准的抗真菌藥物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.這項合作建立在AN2團隊與GSK全球健康研發小組之前的工作基礎之上。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","ANTX":"AN2 Therapeutics, Inc.","LENZ":"Therapeutics","BK4007":"制药","BK4588":"碎股","GSK.UK":"葛兰素史克","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","BK4539":"次新股"},"translate_title":"AN2 Therapeutics and GSK reach a partnership to jointly advance the development of boron-based tuberculosis treatments AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"GSK":1.5,"ANTX":0.9,"GSK.UK":0.6},"content_text":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics與GSK達成了一項研究合作，以開發治療結核病（TB）的新療法。The Gates Foundation will provide an additional year of funding to support AN2’s work within this partnership.蓋茨基金會將提供額外一年的資金，以支持 AN2 在此合作伙伴關係中的工作。Tuberculosis remains one of the world’s most severe health challenges, affecting over a quarter of the global population and causing more than 1.25 million deaths each year. The collaboration aims to develop boron-based leucyl-tRNA synthetase (LeuRS) inhibitors, a new class of compounds targeting novel mechanisms not accessible through conventional carbon-based chemistry..結核病仍然是全球最嚴峻的健康挑戰之一，影響着全球超過四分之一的人口，每年導致超過125萬人死亡。此次合作旨在開發基於硼的亮氨酰-tRNA合成酶（LeuRS）抑制劑，這是一類針對傳統碳基化學無法觸及的新機制的新型化合物。AN2’s boron chemistry platform has shown potential in developing drugs for infectious diseases such as nontuberculous mycobacterial (NTM) lung disease and TB. The same validated LeuRS target forms the basis of several compounds, including epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal..AN2的硼化學平台在開發治療傳染病（如非結核分枝桿菌（NTM）肺病和結核病）藥物方面顯示出潛力。經驗證的LeuRS靶點是多種化合物的基礎，包括用於治療NTM肺病的在研藥物epetraborole、用於治療結核病的在研藥物ganfeborole，以及獲得FDA批准的抗真菌藥物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.這項合作建立在AN2團隊與GSK全球健康研發小組之前的工作基礎之上。它代表了一項共同努力，探索創新方法，可能有助於應對結核病日益加重的負擔，特別是在低收入國家。By combining AN2’s expertise in boron-based drug discovery with GSK’s global health capabilities and continued support from the Gates Foundation, the initiative aims to contribute to the development of new and effective therapies for tuberculosis.通過結合AN2在硼基藥物發現方面的專業知識與GSK的全球健康能力，以及蓋茨基金會的持續支持，該計劃旨在為結核病開發新的有效療法做出貢獻。Source: businesswire.com來源：businesswire.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}